Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Director | June 30, 2026 | July 02, 2026 |
| Keenova Therapeutics plcNONE · Entity 28960 | Director | July 15, 2026 | July 18, 2026 |
| Prelude Therapeutics IncPRLD · Entity 5561 | Director | June 09, 2026 | June 10, 2026 |
| TScan Therapeutics, Inc.TCRX · Entity 7255 | Director | May 20, 2026 | May 22, 2026 |
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | Chief Financial Officer | October 08, 2018 | October 10, 2018 |
| US Ecology, Inc.ECOL · Entity 127674 | Director | May 02, 2022 | May 03, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.66 · Expires 2036-06-29 | Direct | 32,000 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 32,000 · Balance 32,000 F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Keenova Therapeutics plc
Report date July 15, 2026 · Filed July 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 31,406 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 4,406 · Balance 31,406 F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
F2: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders.
Prelude Therapeutics Inc
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-08 | Direct | 38,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
TScan Therapeutics, Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2036-05-20 | Direct | 67,000 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 67,000 · Balance 67,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time.
Tectonic Therapeutic, Inc.
Report date October 08, 2018 · Filed October 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2018-10-08 transaction · row 1
1 source rowRow 1 · 2018-10-08 · Exercise / conversion · Acquired 10,000 · Balance 10,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2027-07-19 | Direct | 148,318 |
Reported balance
After 2018-10-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-08 · Exercise / conversion · Disposed 10,000 · Balance 148,318 F1: 25% of the shares vested on August 28, 2018, and the remaining 75% vest in equal monthly installments thereafter over a three-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares vested on August 28, 2018, and the remaining 75% vest in equal monthly installments thereafter over a three-year period.
US Ecology, Inc.
Report date May 02, 2022 · Filed May 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-02 transaction · row 1
1 source rowRow 1 · 2022-05-02 · Disposition to issuer · Disposed 10,070 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on February 8, 2022, by and among the Issuer, Republic Services, Inc. ("Parent") and Bronco Acquisition Corp. (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on February 10, 2022). At the effective time of the merger, each Issuer share of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $48.00 per share in cash without interest ("Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectRetirement Account | 0 |
Reported balance
After 2022-05-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-05-02 · Disposition to issuer · Disposed 3,430 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on February 8, 2022, by and among the Issuer, Republic Services, Inc. ("Parent") and Bronco Acquisition Corp. (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on February 10, 2022). At the effective time of the merger, each Issuer share of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $48.00 per share in cash without interest ("Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on February 8, 2022, by and among the Issuer, Republic Services, Inc. ("Parent") and Bronco Acquisition Corp. (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on February 10, 2022). At the effective time of the merger, each Issuer share of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $48.00 per share in cash without interest ("Merger Consideration").
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Pandion Therapeutics, Inc.
Report date April 01, 2021 · Filed April 01, 2021
Section 16 reporting ended · disclosed 2021-04-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.96 · Expires 2030-12-01 | Direct | 0 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Disposition to issuer · Disposed 27,994 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. F3: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2: All options were vested and exercisable as of immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price.
F2: All options were vested and exercisable as of immediately prior to the Effective Time.
F3: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
US Ecology Holdings, Inc.
Report date November 01, 2019 · Filed November 01, 2019
Section 16 reporting ended · disclosed 2019-11-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-01 transaction · row 1
1 source rowRow 1 · 2019-11-01 · Disposition to issuer · Disposed 5,170 · Balance 0 F1: Disposed pursuant to that certain Agreement and Plan of Merger, dated as of June 23, 2019, by and among US Ecology Holdings, Inc. (f/k/a US Ecology, Inc.) ("Parent"), NRC Group Holdings Corp., US Ecology, Inc. (f/k/a US Ecology Parent, Inc.) ("Holdco"), ECOL Merger Sub, Inc. ("ECOL Merger Sub") and Rooster Merger Sub, Inc., in a merger transaction in which ECOL Merger Sub merged with and into Parent, and each issued and outstanding share of Parent's common stock was converted into the right to receive, and became exchangeable for, one share of common stock, par value $0.01 of Holdco. |
| Common StockSEC Table I · non-derivative | IndirectRetirement Account | 0 |
Reported balance
After 2019-11-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-01 · Disposition to issuer · Disposed 2,330 · Balance 0 F1: Disposed pursuant to that certain Agreement and Plan of Merger, dated as of June 23, 2019, by and among US Ecology Holdings, Inc. (f/k/a US Ecology, Inc.) ("Parent"), NRC Group Holdings Corp., US Ecology, Inc. (f/k/a US Ecology Parent, Inc.) ("Holdco"), ECOL Merger Sub, Inc. ("ECOL Merger Sub") and Rooster Merger Sub, Inc., in a merger transaction in which ECOL Merger Sub merged with and into Parent, and each issued and outstanding share of Parent's common stock was converted into the right to receive, and became exchangeable for, one share of common stock, par value $0.01 of Holdco. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to that certain Agreement and Plan of Merger, dated as of June 23, 2019, by and among US Ecology Holdings, Inc. (f/k/a US Ecology, Inc.) ("Parent"), NRC Group Holdings Corp., US Ecology, Inc. (f/k/a US Ecology Parent, Inc.) ("Holdco"), ECOL Merger Sub, Inc. ("ECOL Merger Sub") and Rooster Merger Sub, Inc., in a merger transaction in which ECOL Merger Sub merged with and into Parent, and each issued and outstanding share of Parent's common stock was converted into the right to receive, and became exchangeable for, one share of common stock, par value $0.01 of Holdco.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2026 Filed Jul 18, 2026 01:55 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 4,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-084775 · tm2620763-2_4seq1.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,406 Underlying: Ordinary Shares · 4,406 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:30 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193125-26-294699 · ownership.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-29 F1 · derivative.exercise_date: This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 20:15 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantDirector Stock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $3.94 | $0.00 |
DisclosureSEC source: 0001617541-26-000005 · primarydocument.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:12 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 4,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070524 · tm2616870-5_4seq1.xml · derivative · entry 2 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Ordinary Shares · 4,882 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F2 · derivative.expiration_date: The RSUs, which were granted on August 14, 2025, vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:12 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 4,882 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-070524 · tm2616870-5_4seq1.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:05 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001193125-26-236844 · ownership.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Voting Common Stock · 67,000 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) May 20, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| February 23, 2026 Filed Feb 26, 2026 01:48 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 3,984 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-019923 · tm267115-3_4seq1.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,882 Underlying: Ordinary Shares · 3,984 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: Each RSU will fully vest on February 23, 2027. F2 · derivative.expiration_date: Each RSU will fully vest on February 23, 2027. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 1,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-000779 · tm261751-2_4seq1.xml · derivative · entry 4 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,898 Underlying: Ordinary Shares · 1,808 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. F4 · derivative.exercise_date: On February 19, 2024, the Reporting Person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 6 below. F4 · derivative.expiration_date: On February 19, 2024, the Reporting Person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 6 below. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 1,480 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-000779 · tm261751-2_4seq1.xml · derivative · entry 3 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,706 Underlying: Ordinary Shares · 1,480 shares Expires not disclosed F3 · derivative.exercise_price: The Reporting Person entered into an agreement with the Issuer pursuant to which the Reporting Person forfeited the right to receive 1,480 RSUs that would otherwise have vested in exchange for a payment from the Issuer to facilitate the Reporting Person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. F5 · price: The number of RSUs forfeited is based on a percentage. F4 · derivative.exercise_date: On February 19, 2024, the Reporting Person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 6 below. F4 · derivative.expiration_date: On February 19, 2024, the Reporting Person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 6 below. F6 · balance_after: Reflects that the Reporting Person received 5,238 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Tax withholdingOrdinary Shares | 513 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-000779 · tm261751-2_4seq1.xml · nonDerivative · entry 2 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,505 F2 · price: The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 23:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 1,808 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-000779 · tm261751-2_4seq1.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU. Read SEC document |
| October 17, 2025 Filed Oct 20, 2025 20:16 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantDirector Stock Option (Right to Buy) · Derivative | 76,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001617541-25-000005 · primarydocument.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,000 Underlying: Common Stock · 76,000 shares Expires 2035-10-16 F1 · derivative.exercise_date: The option award vests over a three year period equally one-thirty-sixth per month, subject to Reporting Person's continued service to the Company on each vesting date. Read SEC document |
| August 14, 2025 Filed Aug 19, 2025 01:03 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 4,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-079943 · tm2523680-3_4seq1.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,948 Underlying: Ordinary Shares · 4,062 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. F2 · derivative.expiration_date: The RSUs will vest on the earlier of (i) the first anniversary of the grant date and (ii) the date of the Issuer's next annual general meeting of shareholders. Read SEC document |
| July 31, 2025 Filed Aug 5, 2025 00:50 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 16,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-073790 · tm2522414-13_4seq1.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,886 Underlying: Ordinary Shares · 16,414 shares Expires not disclosed F1 · derivative.exercise_price: On July 31, 2025, pursuant to the Transaction Agreement, dated as of March 13, 2025 (as amended, the "Transaction Agreement"), by and among Mallinckrodt plc (the "Issuer"), Endo, Inc. ("Endo") and Salvare Merger Sub LLC, the Issuer's wholly owned subsidiary ("Merger Sub"), the Merger Sub merged with and into Endo (the "Business Combination"), with Endo surviving the Business Combination as a wholly owned subsidiary of the Issuer. F2 · derivative.exercise_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026. F2 · derivative.expiration_date: Upon consummation of the Business Combination, each performance unit ("PSU") held by the reporting person automatically converted into a restricted unit ("RSU"). Each RSU will fully vest on December 25, 2026. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 20:26 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0000950170-25-093021 · ownership.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Voting Common Stock · 67,000 shares Expires 2035-06-30 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 30, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 26, 2025 Filed Jun 30, 2025 20:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $7.38 | $0.00 |
DisclosureSEC source: 0000950170-25-091583 · ownership.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2035-06-25 F1 · derivative.exercise_date: This option was granted on June 26, 2025 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 22:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionRestricted Stock Units · Derivative | 1,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000367 · tm2432211-2_4seq1.xml · derivative · entry 4 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,472 Underlying: Ordinary Shares · 1,504 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU. F4 · derivative.exercise_date: On February 19, 2024, the reporting person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. F4 · derivative.expiration_date: On February 19, 2024, the reporting person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 22:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Disposition to issuerRestricted Stock Units · Derivative | 1,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000367 · tm2432211-2_4seq1.xml · derivative · entry 3 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,976 Underlying: Ordinary Shares · 1,231 shares Expires not disclosed F3 · derivative.exercise_price: The reporting person entered into an agreement with the issuer pursuant to which the reporting person forfeited the right to receive 1,231 RSUs that would otherwise have vested in exchange for a payment from the issuer to facilitate the reporting person's ability to satisfy certain tax obligations related to the RSUs scheduled to vest. F5 · price: The number of RSUs forfeited is based on a percentage. F4 · derivative.exercise_date: On February 19, 2024, the reporting person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. F4 · derivative.expiration_date: On February 19, 2024, the reporting person was granted 8,207 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 22:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Tax withholdingOrdinary Shares | 294 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000367 · tm2432211-2_4seq1.xml · nonDerivative · entry 2 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,210 F2 · price: The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of RSUs is based on a percentage and did not take into account any market value as the issuer's ordinary shares are not listed or quoted on a recognized trading market. Read SEC document |
| January 01, 2025 Filed Jan 2, 2025 22:00 UTC | Keenova Therapeutics plc NONE · Entity 28960 | Exercise / conversionOrdinary Shares | 1,504 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-000367 · tm2432211-2_4seq1.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the issuer at one share per RSU. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 20:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074884 · ownership.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2024 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:20 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 47,500 | $0.00 Strike: $8.88 | $0.00 |
DisclosureSEC source: 0000950170-24-073695 · ownership.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 Underlying: Voting Common Stock · 47,500 shares Expires 2034-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2025 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| February 19, 2024 Filed Feb 20, 2024 21:11 UTC | Keenova Therapeutics plc NONE · Entity 28960 | GrantRestricted Stock Units · Derivative | 8,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-025519 · tm245307-6_4seq1.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,207 Underlying: Ordinary Shares · 8,207 shares Expires not disclosed F1 · derivative.exercise_price: Upon vesting, each restricted stock unit (the "RSU") will be settled in ordinary shares of the issuer at one share per RSU. F2 · derivative.exercise_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024. F2 · derivative.expiration_date: The RSUs will vest ratably on each of the first three anniversaries of January 1, 2024. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0000950170-23-030756 · ownership.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 0 shares Expires 2033-06-26 F1 · derivative.exercise_date: This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:17 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0000899243-23-015642 · doc4.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Voting Common Stock · 35,000 shares Expires 2033-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2024 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 21:00 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0000899243-22-024526 · doc4.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-06-26 F1 · derivative.exercise_date: This option was granted on June 27, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:30 UTC | TScan Therapeutics, Inc. TCRX · Entity 7255 | GrantStock Option (Right to Buy) · Derivative | 9,146 | $0.00 Strike: $3.17 | $0.00 |
DisclosureSEC source: 0000899243-22-020963 · doc4.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,146 Underlying: Voting Common Stock · 9,146 shares Expires 2032-05-31 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 1, 2023 and (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service at such time. Read SEC document |
| May 02, 2022 Filed May 3, 2022 16:29 UTC | US Ecology, Inc. ECOL · Entity 127674 | Disposition to issuerCommon Stock | 3,430 | $48.00 | $164,640.00 |
DisclosureSEC source: 0001437749-22-010680 · rdgdoc.xml · nonDerivative · entry 2 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Retirement Account Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on February 8, 2022, by and among the Issuer, Republic Services, Inc. ("Parent") and Bronco Acquisition Corp. (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on February 10, 2022). At the effective time of the merger, each Issuer share of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $48.00 per share in cash without interest ("Merger Consideration"). F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on February 8, 2022, by and among the Issuer, Republic Services, Inc. ("Parent") and Bronco Acquisition Corp. (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on February 10, 2022). At the effective time of the merger, each Issuer share of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $48.00 per share in cash without interest ("Merger Consideration"). Read SEC document |
| May 02, 2022 Filed May 3, 2022 16:29 UTC | US Ecology, Inc. ECOL · Entity 127674 | Disposition to issuerCommon Stock | 10,070 | $48.00 | $483,360.00 |
DisclosureSEC source: 0001437749-22-010680 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on February 8, 2022, by and among the Issuer, Republic Services, Inc. ("Parent") and Bronco Acquisition Corp. (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on February 10, 2022). At the effective time of the merger, each Issuer share of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $48.00 per share in cash without interest ("Merger Consideration"). F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), entered into on February 8, 2022, by and among the Issuer, Republic Services, Inc. ("Parent") and Bronco Acquisition Corp. (filed as Exhibit 2.1 to the Form 8-K filed with the Securities and Exchange Commission on February 10, 2022). At the effective time of the merger, each Issuer share of common stock issued and outstanding immediately prior to the effective time of the merger was converted into the right to receive $48.00 per share in cash without interest ("Merger Consideration"). Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 21:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0000899243-21-023282 · doc4.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| May 26, 2021 Filed May 28, 2021 13:02 UTC | US Ecology, Inc. ECOL · Entity 127674 | GrantCommon Stock | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-013676 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,070 F1 · price: Restricted stock issued pursuant to US Ecology, Inc.'s director compensation program and the Amended and Restated US Ecology, Inc. Omnibus Incentive Plan. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 19:45 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 27,994 | Not disclosed Strike: $16.96 | Not disclosed |
DisclosureSEC source: 0000899243-21-014444 · doc4.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,994 shares Expires 2030-12-01 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated February 24, 2021, among Pandion Therapeutics, Inc. (the "Company"), Merck Sharp & Dohme Corp. ("Merck") and Panama Merger Sub, Inc. ("Merger Sub"), Merger Sub commenced a tender offer (the "Offer") to purchase all outstanding Company common stock for the price of $60.00 per share in cash (the "Offer Price"). On April 1, 2021, the Offer consummated, after which Merger Sub merged with and into the Company (the "Merger") and the Company became a wholly owned subsidiary of Merck. At the consummation of the Offer and the Merger, respectively, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Offer Price and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were cancelled and converted automatically into the right to receive the Offer Price. F3 · price: Disposed of pursuant to the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F2 · derivative.exercise_date: All options were vested and exercisable as of immediately prior to the Effective Time. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 20:04 UTC | Pandion Therapeutics, Inc. PAND · Entity 11788 | GrantStock Option (right to buy) · Derivative | 27,994 | $0.00 Strike: $16.96 | $0.00 |
DisclosureSEC source: 0000899243-20-032796 · doc4.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,994 Underlying: Common Stock · 27,994 shares Expires 2030-12-01 F1 · derivative.exercise_date: This option award was granted on December 2, 2020. The shares underlying the award vest in equal monthly installments following December 2, 2020 through December 2, 2023, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 14:34 UTC | US Ecology, Inc. ECOL · Entity 127674 | GrantCommon Stock | 3,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-012603 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,170 F1 · price: Restricted stock issued pursuant to US Ecology, Inc.'s director compensation program and Amended and Restated Omnibus Incentive Plan. Read SEC document |
| May 27, 2020 Filed May 29, 2020 15:58 UTC | US Ecology, Inc. ECOL · Entity 127674 | PurchaseCommon Stock | 1,100 | $36.26 | $39,886.00 |
DisclosureSEC source: 0001437749-20-012045 · rdgdoc.xml · nonDerivative · entry 2 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,070 F2 · shares: Shares were purchased by reporting person's retirement account. Read SEC document |
| May 27, 2020 Filed May 29, 2020 15:58 UTC | US Ecology, Inc. ECOL · Entity 127674 | SaleCommon Stock | 1,100 | $36.18 | $39,798.00 |
DisclosureSEC source: 0001437749-20-012045 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,070 F1 · price: Weighted average price of 700 shares sold at $36.17 and 400 shares sold at $36.20. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 14:09 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 18,571 | $0.00 Strike: $15.86 | $0.00 |
DisclosureSEC source: 0000899243-20-000462 · doc4.xml · derivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,571 Underlying: Common Stock · 18,571 shares Expires 2030-01-01 F1 · derivative.exercise_date: This option was granted on January 2, 2020 and is scheduled to vest in equal monthly installments through January 2, 2023, subject to continued service. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 09:38 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | Disposition to issuerCommon Stock | 2,330 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-021150 · rdgdoc.xml · nonDerivative · entry 2 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Retirement Account Disclosed balance after: 0 F1 · price: Disposed pursuant to that certain Agreement and Plan of Merger, dated as of June 23, 2019, by and among US Ecology Holdings, Inc. (f/k/a US Ecology, Inc.) ("Parent"), NRC Group Holdings Corp., US Ecology, Inc. (f/k/a US Ecology Parent, Inc.) ("Holdco"), ECOL Merger Sub, Inc. ("ECOL Merger Sub") and Rooster Merger Sub, Inc., in a merger transaction in which ECOL Merger Sub merged with and into Parent, and each issued and outstanding share of Parent's common stock was converted into the right to receive, and became exchangeable for, one share of common stock, par value $0.01 of Holdco. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 09:38 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | Disposition to issuerCommon Stock | 5,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-021150 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed pursuant to that certain Agreement and Plan of Merger, dated as of June 23, 2019, by and among US Ecology Holdings, Inc. (f/k/a US Ecology, Inc.) ("Parent"), NRC Group Holdings Corp., US Ecology, Inc. (f/k/a US Ecology Parent, Inc.) ("Holdco"), ECOL Merger Sub, Inc. ("ECOL Merger Sub") and Rooster Merger Sub, Inc., in a merger transaction in which ECOL Merger Sub merged with and into Parent, and each issued and outstanding share of Parent's common stock was converted into the right to receive, and became exchangeable for, one share of common stock, par value $0.01 of Holdco. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 12:35 UTC | US Ecology, Inc. ECOL · Entity 127674 | GrantCommon Stock | 2,330 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-021232 · rdgdoc.xml · nonDerivative · entry 2 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Retirement Account Disclosed balance after: 2,330 F1 · price: Acquired pursuant to that certain Agreement and Plan of Merger, dated as of June 23, 2019, by and among US Ecology Holdings, Inc. (f/k/a US Ecology, Inc.) ("Parent"), NRC Group Holdings Corp., US Ecology, Inc. (f/k/a US Ecology Parent, Inc.) ("Holdco"), ECOL Merger Sub, Inc. ("ECOL Merger Sub") and Rooster Merger Sub, Inc., in a merger transaction in which ECOL Merger Sub merged with and into Parent, and each issued and outstanding share of Parent's common stock was converted into the right to receive, and became exchangeable for, one share of common stock, par value $0.01 of Holdco. Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 12:35 UTC | US Ecology, Inc. ECOL · Entity 127674 | GrantCommon Stock | 5,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-021232 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,170 F1 · price: Acquired pursuant to that certain Agreement and Plan of Merger, dated as of June 23, 2019, by and among US Ecology Holdings, Inc. (f/k/a US Ecology, Inc.) ("Parent"), NRC Group Holdings Corp., US Ecology, Inc. (f/k/a US Ecology Parent, Inc.) ("Holdco"), ECOL Merger Sub, Inc. ("ECOL Merger Sub") and Rooster Merger Sub, Inc., in a merger transaction in which ECOL Merger Sub merged with and into Parent, and each issued and outstanding share of Parent's common stock was converted into the right to receive, and became exchangeable for, one share of common stock, par value $0.01 of Holdco. Read SEC document |
| May 22, 2019 Filed May 23, 2019 15:48 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | GrantCommon Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-010743 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,170 F1 · price: Restricted stock issued pursuant to US Ecology, Inc.'s director compensation program and Omnibus Incentive Plan. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 22:11 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0000899243-18-026516 · doc4.xml · derivative · entry 2 Dorton Katina · CIK 0001617541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,318 Underlying: Common Stock · 10,000 shares Expires 2027-07-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares vested on August 28, 2018, and the remaining 75% vest in equal monthly installments thereafter over a three-year period. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 22:11 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Exercise / conversionCommon Stock | 10,000 | $0.91 | $9,100.00 |
DisclosureSEC source: 0000899243-18-026516 · doc4.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 16:59 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | PurchaseCommon Stock | 400 | $74.55 | $29,820.00 |
DisclosureSEC source: 0001437749-18-017056 · rdgdoc.xml · nonDerivative · entry 2 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,870 F1 · shares: Shares were purchased by the reporting person's retirement account. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 16:59 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | SaleCommon Stock | 1,400 | $74.55 | $104,370.00 |
DisclosureSEC source: 0001437749-18-017056 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,870 Read SEC document |
| May 23, 2018 Filed May 25, 2018 16:16 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | GrantCommon Stock | 1,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-010741 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,270 F1 · price: Restricted stock issued pursuant to US Ecology, Inc.'s director compensation program and Omnibus Incentive Plan. Read SEC document |
| August 25, 2017 Filed Aug 25, 2017 17:49 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | PurchaseCommon Stock | 600 | $47.16 | $28,293.00 |
DisclosureSEC source: 0001437749-17-015348 · rdgdoc.xml · nonDerivative · entry 2 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,970 F1 · shares: Shares were purchased by the reporting person's retirement account. Read SEC document |
| August 25, 2017 Filed Aug 25, 2017 17:49 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | SaleCommon Stock | 600 | $47.15 | $28,287.00 |
DisclosureSEC source: 0001437749-17-015348 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,970 Read SEC document |
| May 24, 2017 Filed May 25, 2017 17:18 UTC | US Ecology Holdings, Inc. ECOL · Entity 154125 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-010109 · rdgdoc.xml · nonDerivative · entry 1 Dorton Katina · CIK 0001617541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,570 F1 · price: Restricted stock issued pursuant to US Ecology, Inc.'s director compensation program and Omnibus Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.